Lilly submits New Drug Application to the FDA for lasmiditan for acute treatment of migraine, receives Breakthrough Therapy Designation for Emgality ™ (galcanezumab-gnlm) for prevention of episodic cluster headache
Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine with or without aura in adults. Lasmiditan is an investigational, oral, centrally-penetrant, selective serotonin 5-HT1F agonist that is structurally and mechanistically distinct from other approved migraine therapies and lacks vasoconstrictive activity. (Source: World Pharma News)
Source: World Pharma News - November 15, 2018 Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news

Scorpion venom to shuttle drugs into the brain
The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a small molecule (peptide) derived from chlorotoxin, found in scorpion venom (Giant Yellow Israeli scorpion), to carry drugs across the blood-brain barrier (BBB). (Source: World Pharma News)
Source: World Pharma News - November 15, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Abbott recommends rejection of below-market mini-Ttender offer by Baker Mills LLC
Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approximately 0.003 percent of the company's outstanding shares. (Source: World Pharma News)
Source: World Pharma News - November 14, 2018 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news

Patient engagement as a new blockbuster drug, not quite yet, study finds
If patient engagement is the new 'blockbuster drug,' why are we not seeing spectacular effects? A team of researchers from The Dartmouth Institute for Health Policy and Clinical Practice and the Berkeley School of Public Health at UC Berkeley recently conducted a study designed to help answer that question and to better understand how patient engagement and activation (PAE) practices (Source: World Pharma News)
Source: World Pharma News - November 14, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AstraZeneca to divest US Synagis rights to Sobi
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction. (Source: World Pharma News)
Source: World Pharma News - November 13, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Obesity both feeds tumors and helps immunotherapy kill cancer
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors. The paradoxical findings, published today in Nature Medicine, give cancer doctors important new information when choosing drugs and other treatments for cancer patients. (Source: World Pharma News)
Source: World Pharma News - November 12, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA highlights record-breaking number of generic drug approvals in October
Today, the U.S. Food and Drug Administration is providing a summary of the generic drug approval actions for the month of October 2018 as part of its efforts to improve patient access to high-quality, lower cost, safe and effective medicines. In October, the FDA approved 110 generic drugs and tentatively approved 18 generic drugs, for a total of 128 approval actions. (Source: World Pharma News)
Source: World Pharma News - November 9, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Blue light can reduce blood pressure
Exposure to blue light decreases blood pressure, reducing the risk of developing cardiovascular disease, a new study from the University of Surrey and Heinrich Heine University Dusseldorf in collaboration with Philips reports. During this study, published in the prestigious European Journal of Preventative Cardiology, participants were exposed to 30 minutes of whole-body blue light at approximately 450 nanometres, a dose comparable to daily sunlight - followed by exposure to a control light on a different day. (Source: World Pharma News)
Source: World Pharma News - November 8, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease
Embark Biotech ApS and Novo Nordisk A/S have entered into a research collaboration focusing on the discovery of novel treatments for obesity and its associated metabolic pathologies through mechanisms that increase energy expenditure. (Source: World Pharma News)
Source: World Pharma News - November 8, 2018 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Gap in research means millions living with long-term consequences of cancer
Millions of people are living with the long-term consequences of cancer and its treatment, but currently there is very little research on the problems they face and how these can be tackled, according to the UK's National Cancer Research Institute (NCRI). Thanks to successes in research on diagnosing and treating cancer, more people are living longer with cancer and with the lasting side-effects of treatments. (Source: World Pharma News)
Source: World Pharma News - November 7, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA grants priority review for Dupixent ® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. (Source: World Pharma News)
Source: World Pharma News - November 7, 2018 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Tumour immune cells could aid cancer therapies
A pioneering technique designed to spot differences between immune cells in tumours could speed the development of cancer treatments, research suggests. Scientists say the approach could be used to help doctors choose the best treatments for individual patients and predict which tumours are likely to respond to a particular therapy. (Source: World Pharma News)
Source: World Pharma News - November 6, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. (Source: World Pharma News)
Source: World Pharma News - November 6, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

21st Annual Superbugs & Superdrugs Conference
18 - 19 March 2019, London, UK. As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. (Source: World Pharma News)
Source: World Pharma News - November 5, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Novartis R & D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
Throughout 2018, Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division, resulting in an industry leading pipeline. Today Novartis holds an R&D and investor update in London which will provide deeper insights into the pipeline including the below. (Source: World Pharma News)
Source: World Pharma News - November 5, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Can chocolate, tea, coffee and zinc help make you more healthy?
Ageing and a low life expectancy are caused, at least partly, by oxidative stress. A team of researchers led by Prof. Dr. Ivana Ivanovi-Burmazovi from the Chair of Bioinorganic Chemistry at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), together with researchers from the USA, have discovered that zinc can activate an organic molecule, helping to protect against oxidative stress. (Source: World Pharma News)
Source: World Pharma News - November 2, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Twenty years on, measuring the impact of human stem cells
In November 1998, the world was introduced to human embryonic stem cells, the blank slate cells that arise at the earliest stages of development and that go on to become any of the scores of cell types that make up a human. In a succinct paper published in the journal Science and heralded around the world, University of Wisconsin-Madison developmental biologist James Thomson described the first successful derivation and culturing of the master cells of life. (Source: World Pharma News)
Source: World Pharma News - November 1, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Amgen Foundation deepens commitment to aspiring scientists worldwide by expanding Amgen Scholars Program
The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a summer at one of many of the world's premier research institutions. The new four-year, $21 million commitment brings the program to a total of 24 elite institutions across the U.S., Europe, Asia and, for the first time, Australia and Canada. (Source: World Pharma News)
Source: World Pharma News - November 1, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Breakthrough neurotechnology for treating paralysis
Three paraplegics who sustained cervical spinal cord injuries many years ago are now able to walk with the aid of crutches or a walker thanks to new rehabilitation protocols that combine targeted electrical stimulation of the lumbar spinal cord and weight-assisted therapy. This latest study, called STIMO (STImulation Movement Overground), establishes a new therapeutic framework to improve recovery from spinal cord injury. (Source: World Pharma News)
Source: World Pharma News - October 31, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Boehringer Ingelheim inaugurates new centre for agile working methods
Boehringer Ingelheim has taken an important step towards greater agility in the company with inauguration of the new building, called "BI CUBE", at the Ingelheim site. The sustainably built and innovative building was handed over to its future users at an internal ceremony. (Source: World Pharma News)
Source: World Pharma News - October 31, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Economic impact of excess weight now exceeds $1.7 trillion
The impact of obesity and overweight on the U.S. economy has eclipsed $1.7 trillion, an amount equivalent to 9.3 percent of the nation's gross domestic product, according to a new Milken Institute report on the role excess weight plays in the prevalence and cost of chronic diseases. The estimate includes $480.7 billion in direct health-care costs and $1.24 trillion in lost productivity, as documented in (Source: World Pharma News)
Source: World Pharma News - October 30, 2018 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Agreement with Gr ünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca's three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. (Source: World Pharma News)
Source: World Pharma News - October 30, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

World Stroke Day - SVIN latest clinical trials and breaking science news
The Society of Vascular and Interventional Neurology (SVIN) would like to announce today on World Stroke Day that it stands committed to the advancement of scientific research to improve the lives of stroke (aka brain-attack) patients worldwide. Stroke and interventional neurologists, who are members of the SVIN, working collaboratively with interventional neuro-radiologists and endovascular (Source: World Pharma News)
Source: World Pharma News - October 29, 2018 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919). (Source: World Pharma News)
Source: World Pharma News - October 29, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

FDA approves new drug to treat influenza
The U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours. (Source: World Pharma News)
Source: World Pharma News - October 26, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

New epigenetic drug strategy to treat cancer
Researchers have discovered that inhibiting CDK9, a DNA transcription regulator, reactivates genes that have been epigenetically silenced by cancer. Reactivation leads to restored tumor suppressor gene expression and enhanced anti-cancer immunity. It is the first time this particular kinase has been linked to gene silencing in mammals. (Source: World Pharma News)
Source: World Pharma News - October 25, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. Xofluza is a first-in-class, single-dose oral medicine with a novel proposed mechanism of action that inhibits polymerase acidic endonuclease, an enzyme essential for viral replication. (Source: World Pharma News)
Source: World Pharma News - October 25, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
AstraZeneca, and its global biologics research and development arm MedImmune, announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company's oncology portfolio and bringing new medicines to patients more quickly. (Source: World Pharma News)
Source: World Pharma News - October 24, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Largest census of cancer genes to help understand drug targets
Researchers at the Wellcome Sanger Institute have created the first comprehensive summary of all genes known to be involved in human cancer, the "Cancer Gene Census". Describing all genes strongly implicated in causing cancer, the Census also describes how they function across all forms of this disease. Reported in Nature Reviews Cancer, the resource catalogues over 700 genes, to help scientists understand the causes of cancers, find drug targets and design treatments. (Source: World Pharma News)
Source: World Pharma News - October 24, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA launches global operation to crack down on websites selling illegal, potentially dangerous drugs
The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, acted this week to target 465 websites that illegally sell potentially dangerous, unapproved versions of opioid, oncology and antiviral prescription drugs to U.S. consumers. (Source: World Pharma News)
Source: World Pharma News - October 23, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Alcon to develop SMART Suite digital health platform for cataract surgery
Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to streamline, simplify and improve cataract surgery for surgeons and patients. (Source: World Pharma News)
Source: World Pharma News - October 23, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Immunotherapy may become new first line treatment in some metastatic colorectal cancers
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich. (1) The drug combination shrank tumours and had beneficial effects on survival in patients with microsatellite instabiliy (MSI)-high metastatic colorectal cancer. (Source: World Pharma News)
Source: World Pharma News - October 22, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves asthma indication for Dupixent ® (dupilumab)
The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. (Source: World Pharma News)
Source: World Pharma News - October 22, 2018 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Amgen invests £50 million ($66 Million) in Oxford Nanopore Technologies
Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. (Source: World Pharma News)
Source: World Pharma News - October 19, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Eating leafy greens could help prevent macular degeneration
A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-related macular degeneration (AMD). Researchers at the Westmead Institute for Medical Research interviewed more than 2,000 Australian adults aged over 49 and followed them over a 15-year period. (Source: World Pharma News)
Source: World Pharma News - October 18, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced that they were granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment of pancreatic cancer. (Source: World Pharma News)
Source: World Pharma News - October 18, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Targeted drugs for advanced cancer move from specialist units to community setting
Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours. This achievement, to be reported at the ESMO 2018 Congress in Munich,(1) shows that cutting-edge precision medicine is spreading from highly specialist cancer units to other healthcare facilities so more patients can benefit, wherever they are treated. (Source: World Pharma News)
Source: World Pharma News - October 17, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Amgen launches AMGEVITATM (Biosimilar Adalimumab) In markets across Europe
Amgen (NASDAQ:AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of (Source: World Pharma News)
Source: World Pharma News - October 17, 2018 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx ® leadership in spondyloarthritis
Novartis, a leader in immuno-dermatology and rheumatology, announced today it will be presenting five-year data from the ongoing extensions of the phase III FUTURE 1 and MEASURE 1 studies for Cosentyx® (secukinumab) in patients with psoriatic arthritis (PsA)[1] and ankylosing spondylitis (AS)[2] respectively. (Source: World Pharma News)
Source: World Pharma News - October 16, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Diets rich in fish oil could slow the spread and growth of breast cancer cells
Omega-3 fatty acids, such as those typically contained in fish oil, may suppress the growth and spread of breast cancer cells in mice. This is according to a new study in the journal Clinical & Experimental Metastasis, which is published under the Springer imprint. According to lead author, Saraswoti Khadge of the University of Nebraska Medical Centre in the US, fatty acids stopped further delayed tumors from forming, and (Source: World Pharma News)
Source: World Pharma News - October 16, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India
Boehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 2018, October 15 the company would like to draw attention to the hygienic conditions in the impoverished regions around the world. (Source: World Pharma News)
Source: World Pharma News - October 15, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Abbott names Robert B. Ford president, chief operating officer
Abbott (NYSE: ABT) announced today that Robert B. Ford has been named president and chief operating officer, effective immediately. Mr. Ford, a 22-year Abbott veteran, was most recently executive vice president of Medical Devices, Abbott's largest business. (Source: World Pharma News)
Source: World Pharma News - October 15, 2018 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humira®* (adalimumab). (Source: World Pharma News)
Source: World Pharma News - October 12, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Cancer stem cells use normal genes in abnormal ways
CDK1 is a "normal" protein - its presence drives cells through the cycle of replication. And MHC Class I molecules are "normal" as well - they present bits of proteins on the surfaces of cells for examination by the immune system. But a University of Colorado Cancer Center study published in the journal Cancer Research shows that a population of cancer cells marked by MHC Class I molecules and high CDK1 is anything but normal. (Source: World Pharma News)
Source: World Pharma News - October 12, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors
Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab), (Source: World Pharma News)
Source: World Pharma News - October 11, 2018 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

SMi Group announces the 10th Annual RNA Therapeutics Conference
20 - 21 February 2019, London, UK. Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come. (Source: World Pharma News)
Source: World Pharma News - October 11, 2018 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Organs-on-chip technology reveals new drug candidates for Lou Gehrig's disease
The investigation of amyotrophic lateral sclerosis (ALS) - also known as Lou Gehrig's disease - through muscle-on-a-chip technology has revealed a new drug combination that may serve as an effective treatment of the progressive neurodegenerative disease. These findings highlight organ-on-a-chip technologies - in which live conditions of the body are mimicked in a microfluidic cell culture - as promising platforms for (Source: World Pharma News)
Source: World Pharma News - October 10, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets)
Merck, the vibrant science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets) at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, Germany. (Source: World Pharma News)
Source: World Pharma News - October 10, 2018 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Pfizer announces Executive Leadership Team
Pfizer Inc. (NYSE:PFE) today announced its executive team that will report to Albert Bourla, incoming Chief Executive Officer, coincident with the commencement of his new role effective January 1, 2019. (Source: World Pharma News)
Source: World Pharma News - October 9, 2018 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Seed oils are best for LDL cholesterol
If you want to lower your low-density lipoprotein cholesterol, called LDL or, colloquially, "bad cholesterol," the research is clear about one thing: You should exchange saturated fats with unsaturated fat. If you want to know what you should use to sauté your dinner, that's a harder question to answer. Many of the studies establishing that mono- and polyunsaturated fats are better for blood lipids than (Source: World Pharma News)
Source: World Pharma News - October 9, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news